Nanoscope Therapeutics Featured at EUretina Congress in Barcelona

Nanoscope Therapeutics Inc., a biotechnology firm focused on developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy secondary to macular degeneration, announced their participation at the 24th Euretina congress in Barcelona, Spain, from September 19-22, 2024.

One of the key presentations will cover the longitudinal analysis of best corrected visual acuity (BCVA) in patients treated with MCO-010, a mutation-agnostic optogenetic therapy for retinitis pigmentosa. This session is set for September 21, 2024, at 9:36 am CEST, featuring results from the 100-week TOPLINE Phase 2b/3 clinical trial named RESTORE. The presentation will be held at location 115 in the Barcelona International Convention Center and will be presented by Dr. Jordi Monés, the Director of Institut de la Màcula and Barcelona Macula Foundation. Dr. Monés will present efficacy analyses that use the area under the curve (AUC) method to capture treatment benefits over a two-year observation period.

In addition to this, Dr. Monés will chair a symposium on optogenetics therapeutics for IRDs and geographic atrophy. This symposium will occur on September 20, 2024, from 9:45 am to 10:45 am CEST at location 118/119 in the Barcelona International Convention Center. Key presentations within the symposium will include:

- Opening Remarks by Dr. Jordi Monés
- Discussion on Degenerative Retinal Diseases by Dr. Arshad Khanani from the USA
- Overview of Optogenetic Therapies for IRDs by Dr. Paulo Stanga from the UK
- Insights into Optogenetic Therapies for Macular Degeneration by Dr. Jordi Monés
- Imaging and Efficacy Evaluations in Low-Vision Patients Treated with Optogenetics by Dr. Usha Chakravarthy from the UK
- A Q&A session moderated by Prof. Francesco Bandello from Italy, featuring all speakers.

The management team from Nanoscope Therapeutics will be present at the conference and available for meetings.

Nanoscope Therapeutics is at the forefront of developing gene-agnostic, sight-restoring optogenetic therapies aimed at treating millions of patients suffering from retinal degenerative diseases. Their leading product, MCO-010, has recently shown promising results from the RESTORE Phase 2b clinical trial in the U.S. for retinitis pigmentosa. Additionally, the company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients and has plans to initiate a Phase 3 registrational trial. MCO-010 has received Fast Track designations and orphan drug designations from the FDA for both retinitis pigmentosa and Stargardt disease. Nanoscope’s preclinical assets also include MCO-020, a non-viral laser-delivered gene therapy for geographic atrophy.